Effective April 1, 2013, IBC has designated Orthovisc
?,
Synvisc
?, and Synvisc-One
? as our preferred hyaluronate
acid products for the treatment of osteoarthritis of the knee.
We encourage providers to choose one of the three preferred products when
treating members who have osteoarthritis of the knee.
For additional information on the three preferred products to treat
osteoarthritis of the knee, read the news article, [
]Orthovisc? replaces
Euflexxa? as one of three preferred products to treat osteoarthritis
of the knee[], located on our Medical Policy portal.